PEG-MGF: The IGF-1 Splice Variant and What PEGylation Does

PEG-MGF is a polyethylene glycol conjugate of a 24 amino acid peptide corresponding to the C-terminal end of the IGF-1Eb splice variant, the sequence that got labelled mechano-growth factor in the late 1990s. Two separate things are going on in that description, and both deserve scrutiny: the biology of the IGF-1 splice variant, which is real and well documented, and the existence of a free MGF peptide as a distinct molecular species, which is contested in the primary literature. We go through both below, along with what PEGylation actually does to a peptide.

Where the sequence comes from

The IGF-1 gene is alternatively spliced. One product resembles the main liver form and behaves as an endocrine signal; another carries a different 3-prime exon sequence and was proposed to act locally [1]. McKoy and colleagues measured both in rabbit extensor digitorum longus muscle using RNase protection assays. Stretch by plaster cast immobilisation markedly upregulated both IGF-1 mRNA forms within 4 days. Stretch combined with 10 Hz electrical stimulation produced an even larger increase. Electrical stimulation without stretch produced no significant change over sham-operated controls [1].

That last comparison is the informative one. Mechanical load, not electrical activity, was what moved the transcript, which is where the mechano part of the name came from.

The peptide sold as MGF is not that transcript. It is a synthetic 24-residue sequence matching the C-terminal end of the unprocessed IGF-1Eb precursor, cleaved in principle from the N-terminal 70-residue mature IGF-1 protein [3][4].

The claim, and the failure to reproduce it

Yang and Goldspink’s 2002 paper is the origin of most downstream claims. Working in an in vitro cell model, they reported that the distinct E domain of MGF inhibited terminal differentiation while increasing myoblast proliferation, unlike mature IGF-1, and that blocking the IGF-1 receptor with a specific antibody indicated the E domain effect was mediated through a different receptor [2]. A separate receptor would be a substantial finding.

It has not held up well. Fornaro and colleagues, working at two pharmaceutical companies, set out specifically to reproduce it and could not. Peptide concentrations up to 500 ng/ml failed to increase proliferation of C2C12 cells or primary human skeletal myoblasts, while all the same cell types did respond to mature IGF-1 and to full-length IGF-1Eb. The peptide also failed to inhibit differentiation of myoblasts into myotubes, and the authors extended the work to primary mouse cells to rule out a tissue culture line artefact [4].

Matheny, Nindl and Adamo’s review lands on the deeper issue. The transcript story is solid: IGF-1Eb mRNA goes up first after mechanical stress, IGF-1Ea later. But as they put it, no analogous peptide product of the Igf1 gene has been identified in or isolated from cultured cells, their conditioned medium, or animals [3]. The synthetic peptide exists. Whether the body ever makes a free version of it is an open question.

We’d summarise the state of play like this:

Other published work on the peptide

One finding from a different system is worth noting because it is independent of the myoblast literature. Dluzniewska and colleagues tested the synthetic C-terminal peptide in a gerbil model of transient brain ischemia and in an organotypic hippocampal culture model, and reported protection of vulnerable neurons in both. In culture it was as potent as full-length IGF-1 and its effect lasted longer, and the action did not depend on the IGF-1 receptor [5]. Endogenous expression also rose in the ischemia-resistant neurons in their model.

That paper is from 2005 and, as with the proliferation work, we are not aware of a large independent replication. Treat it as a single reported result rather than a settled mechanism.

What the PEG actually does

PEGylation means covalently attaching one or more polyethylene glycol chains to a molecule. Veronese and Pasut summarise the consequences: longer residence in the body, less degradation by metabolic enzymes, and reduced or eliminated immunogenicity of protein conjugates, with PEG itself being water soluble and non-immunogenic [6].

A few mechanical details follow from that, and they matter more for a small peptide than for a protein:

• A 24-residue peptide is around 2.9 kDa. A 5 kDa or 20 kDa PEG chain is therefore larger than the peptide it is attached to, and dominates the conjugate’s hydrodynamic size.
• The attachment chemistry decides the site. Amine-directed chemistry targets lysines and the N terminus, so a peptide with several lysines gives a mixture of positional isomers unless the reaction is controlled.
• Any PEG preparation is a distribution of chain lengths, not one molecular weight, which is why mass spectrometry of a PEGylated peptide gives a series of peaks rather than one.
• Shielding cuts both ways. The same bulk that slows enzymes can reduce binding to whatever target the peptide has.

Muttenthaler and colleagues cover conjugation and other half-life extension strategies in their survey of how peptide chemistry developed [7]. The general point stands: a PEGylated peptide is a different chemical entity from the parent, with its own impurity profile and its own characterisation requirements.

Characterisation and handling

PEGylated peptides are harder to analyse than unmodified ones, and a certificate that treats them identically is not telling you much. Reversed phase HPLC still gives a purity figure, but the PEG distribution broadens peaks, so resolution between the conjugate and unreacted peptide is the thing to look for. Mass spectrometry confirms conjugation occurred, showing the characteristic PEG envelope rather than a single mass. Free PEG and unreacted starting peptide are the two impurities that matter most, and both should be addressed explicitly.

Stability follows the usual peptide rules plus one extra: polyethylene glycol chains oxidise, and oxidative degradation of the polymer is a known failure route alongside the deamidation, isomerisation and hydrolysis that affect the peptide portion [8]. Keep the lyophilised solid cold, dry and out of light, and expect solutions to be short-lived.

Our analytical reports are published on the COA page, with more on how that testing works in our article on third party tested material. For the underlying chemistry of how these sequences are assembled, see our overview of peptides and polypeptides.

FAQ

Is MGF the same molecule as IGF-1?

No. MGF names a splice variant of the IGF-1 gene, and the peptide sold under that name is the 24 C-terminal residues of the IGF-1Eb precursor, not mature IGF-1 [3].

Why does PEG-MGF have a different molecular weight on every report?

Because PEG is polydisperse. Mass spectrometry of a PEGylated peptide returns a distribution of masses spaced by the repeat unit, not a single value [6].

How strong is the evidence for the peptide’s reported cellular effects?

Weak. The 2002 proliferation finding [2] was not reproduced in a 2014 study using the same cell types at concentrations up to 500 ng/ml [4], and no endogenous free peptide has been isolated [3].

References

1. McKoy G, Ashley W, Mander J, et al. Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiol. 1999. PMID 10087355
2. Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002. PMID 12095637
3. Matheny RW Jr, Nindl BC, Adamo ML. Minireview: mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010. PMID 20130113
4. Fornaro M, Hinken AC, Needle S, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab. 2014. PMID 24253050
5. Dluzniewska J, Sarnowska A, Beresewicz M, et al. A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB J. 2005. PMID 16144956
6. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005. PMID 16243265
7. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021. PMID 33536635
8. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010. PMID 20143256